- Home
- ANIP
as 07-26-2024 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $83.67 | AVG Volume (30 days): | 172.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $48.20 - $70.81 | Next Earning Date: | 08-07-2024 |
| Revenue: | $517,460,000 | Revenue Growth: | 44.26% |
| Revenue Growth (this year): | 13.69% | Revenue Growth (next year): | 6.64% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jul 18 '24 | Sell | $62.00 | 2,743 | $170,066.00 | 632,620 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jul 15 '24 | Sell | $63.16 | 14,257 | $900,472.12 | 635,363 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jul 15 '24 | Sell | $64.27 | 22,000 | $1,413,940.00 | 649,620 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jul 15 '24 | Sell | $63.38 | 11,000 | $697,180.00 | 671,620 | SEC Form 4 |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jul 12 '24 | Sell | $64.91 | 250 | $16,227.50 | 58,981 | SEC Form 4 |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | Jul 1 '24 | Sell | $63.44 | 20,000 | $1,268,800.00 | 193,226 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jun 21 '24 | Sell | $58.90 | 20,000 | $1,178,000.00 | 682,620 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jun 17 '24 | Sell | $61.41 | 7,946 | $487,963.86 | 724,674 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jun 17 '24 | Sell | $60.76 | 10,607 | $644,481.32 | 714,067 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Jun 17 '24 | Sell | $59.86 | 11,447 | $685,217.42 | 702,620 | SEC Form 4 |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jun 13 '24 | Sell | $63.80 | 250 | $15,950.00 | 59,231 | SEC Form 4 |
| CAREY STEPHEN P. | ANIP | SVP & CFO | Jun 4 '24 | Sell | $63.58 | 5,000 | $317,900.00 | 161,968 | SEC Form 4 |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | Jun 3 '24 | Sell | $64.41 | 20,000 | $1,288,200.00 | 213,226 | SEC Form 4 |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | May 21 '24 | Sell | $61.61 | 2,000 | $123,220.00 | 83,277 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 20 '24 | Sell | $61.81 | 12,855 | $794,567.55 | 732,620 | SEC Form 4 |
| TANNENBAUM RENEE P | ANIP | Director | May 16 '24 | Sell | $63.87 | 2,000 | $127,740.00 | 18,211 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 15 '24 | Sell | $65.86 | 14,850 | $978,021.00 | 767,770 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 15 '24 | Sell | $63.84 | 16,459 | $1,050,742.56 | 751,311 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 15 '24 | Sell | $62.09 | 5,836 | $362,357.24 | 745,475 | SEC Form 4 |
| Lalwani Nikhil | ANIP | PRESIDENT & CEO | May 14 '24 | Sell | $66.10 | 16,669 | $1,101,820.90 | 377,505 | SEC Form 4 |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | May 13 '24 | Sell | $67.69 | 250 | $16,922.50 | 59,481 | SEC Form 4 |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | May 1 '24 | Sell | $66.62 | 20,000 | $1,332,400.00 | 233,226 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Apr 18 '24 | Sell | $64.98 | 10,423 | $677,286.54 | 799,429 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Apr 18 '24 | Sell | $65.17 | 16,809 | $1,095,442.53 | 782,620 | SEC Form 4 |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | Apr 15 '24 | Sell | $66.33 | 7,414 | $491,770.62 | 825,206 | SEC Form 4 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
ANIP: Raising target price to $68.00
Zacks
9 days ago
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Argus Research
10 days ago
ANIP: Raising target price to $67.00
MT Newswires
11 days ago
ANI Pharmaceuticals Launches L-Glutamine Oral Powder Following FDA Approval
GlobeNewswire
12 days ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
Argus Research
17 days ago
ANIP: Lowering target price to $64.00
MT Newswires
25 days ago
ANI Pharmaceuticals Receives FDA Approval for Naproxen Delayed-Release Tablets
GlobeNewswire
25 days ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.